Kiromic BioPharma, Inc. is a preclinical stage biopharmaceutical company. The Company is focused on discovering, developing, and commercializing immune-oncology and small molecule therapy. The Company is developing CAR cell product candidates known as ALEXIS (Allogenic Lead Exogenous Isoforms). These are designed to treat cancer and to destroy cancer cells. The Company is developing product candidates that targets for blood cancers, including large B cell lymphoma, and targets solid tumors, such as malignant pleural mesothelioma (lung) and epithelial ovarian cancer. The Company’s product pipeline includes ALEXIS AIDT-1, is allogenic CAR cell product candidate targeting AIDT-1; ALEXIS AIDT-2 EOC, is allogenic CAR cell product candidate targeting AIDT-2 and ALEXIS AIDT-2 MPM, is allogenic CAR/NKT-Like cell product candidate targeting AIDT-2.